OBJECTIVE: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. PATIENTS AND METHODS: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m2 every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg). Based on the results of the phase 1 study, the investigation was expanded into a randomized study of docetaxel with prednisone (hereafter 'docetaxel/prednisone') plus the maximum tolerated dose (MTD) of cabozantinib compared with docetaxel/prednisone alone. RESULTS: A total of 44 men with mCRPC were enrolled in this phase 1/2 trial. An MTD of 40 mg cabozantinib plus docetaxel/prednisone was determined. Dose-limiting toxicities were neutropenic fever and palmar-plantar erythrodysesthesia, and there was one death attributable to a thromboembolic event. In addition, grade 3 or 4 myelosuppression, hypophosphataemia and neuropathy were seen in three or more patients. In the phase 1 study, the median time to progression (TTP) and overall survival (OS) time were 13.6 and 16.3 months, respectively. In the phase 2 study, which was terminated early because of poor accrual, the median TTP and OS favoured the combination (n = 13) compared to docetaxel/prednisone alone (n = 12; 21.0 vs 6.6 months; P = 0.035 and 23.8 vs 15.6 months; P = 0.072, respectively). CONCLUSION: Despite the limited number of patients in this study, preliminary data suggest that cabozantinib can be safely added to docetaxel/prednisone with possible enhanced efficacy. Published 2020. This article is a US Government work and is in the public domain in the USA.
OBJECTIVE: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. PATIENTS AND METHODS: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m2 every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg). Based on the results of the phase 1 study, the investigation was expanded into a randomized study of docetaxel with prednisone (hereafter 'docetaxel/prednisone') plus the maximum tolerated dose (MTD) of cabozantinib compared with docetaxel/prednisone alone. RESULTS: A total of 44 men with mCRPC were enrolled in this phase 1/2 trial. An MTD of 40 mg cabozantinib plus docetaxel/prednisone was determined. Dose-limiting toxicities were neutropenic fever and palmar-plantar erythrodysesthesia, and there was one death attributable to a thromboembolic event. In addition, grade 3 or 4 myelosuppression, hypophosphataemia and neuropathy were seen in three or more patients. In the phase 1 study, the median time to progression (TTP) and overall survival (OS) time were 13.6 and 16.3 months, respectively. In the phase 2 study, which was terminated early because of poor accrual, the median TTP and OS favoured the combination (n = 13) compared to docetaxel/prednisone alone (n = 12; 21.0 vs 6.6 months; P = 0.035 and 23.8 vs 15.6 months; P = 0.072, respectively). CONCLUSION: Despite the limited number of patients in this study, preliminary data suggest that cabozantinib can be safely added to docetaxel/prednisone with possible enhanced efficacy. Published 2020. This article is a US Government work and is in the public domain in the USA.
Authors: Himisha Beltran; Andrew Hruszkewycz; Howard I Scher; Jeffrey Hildesheim; Jennifer Isaacs; Evan Y Yu; Kathleen Kelly; Daniel Lin; Adam Dicker; Julia Arnold; Toby Hecht; Max Wicha; Rosalie Sears; David Rowley; Richard White; James L Gulley; John Lee; Maria Diaz Meco; Eric J Small; Michael Shen; Karen Knudsen; David W Goodrich; Tamara Lotan; Amina Zoubeidi; Charles L Sawyers; Charles M Rudin; Massimo Loda; Timothy Thompson; Mark A Rubin; Abdul Tawab-Amiri; William Dahut; Peter S Nelson Journal: Clin Cancer Res Date: 2019-07-30 Impact factor: 12.531
Authors: Ravi A Madan; Fatima H Karzai; Yang-Min Ning; Bamidele A Adesunloye; Xuan Huang; Nancy Harold; Anna Couvillon; Guinevere Chun; Lisa Cordes; Tristan Sissung; Shaunna L Beedie; Nancy A Dawson; Marc R Theoret; David G McLeod; Inger Rosner; Jane B Trepel; Min-Jung Lee; Yusuke Tomita; Sunmin Lee; Clara Chen; Seth M Steinberg; Philip M Arlen; James L Gulley; William D Figg; William L Dahut Journal: BJU Int Date: 2016-02-19 Impact factor: 5.588
Authors: William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: Ethan M Basch; Mark Scholz; Johann S de Bono; Nicholas Vogelzang; Paul de Souza; Gavin Marx; Ulka Vaishampayan; Saby George; James K Schwarz; Emmanuel S Antonarakis; Joseph M O'Sullivan; Arash Rezazadeh Kalebasty; Kim N Chi; Robert Dreicer; Thomas E Hutson; Amylou C Dueck; Antonia V Bennett; Erica Dayan; Milan Mangeshkar; Jaymes Holland; Aaron L Weitzman; Howard I Scher Journal: Eur Urol Date: 2018-12-04 Impact factor: 20.096
Authors: Yang-Min Ning; James L Gulley; Philip M Arlen; Sukyung Woo; Seth M Steinberg; John J Wright; Howard L Parnes; Jane B Trepel; Min-Jung Lee; Yeong Sang Kim; Haihao Sun; Ravi A Madan; Lea Latham; Elizabeth Jones; Clara C Chen; William D Figg; William L Dahut Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Sheng Yu Ku; Spencer Rosario; Yanqing Wang; Ping Mu; Mukund Seshadri; Zachary W Goodrich; Maxwell M Goodrich; David P Labbé; Eduardo Cortes Gomez; Jianmin Wang; Henry W Long; Bo Xu; Myles Brown; Massimo Loda; Charles L Sawyers; Leigh Ellis; David W Goodrich Journal: Science Date: 2017-01-06 Impact factor: 47.728
Authors: Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola Journal: N Engl J Med Date: 2015-08-05 Impact factor: 91.245
Authors: Fatima Karzai; David VanderWeele; Ravi A Madan; Helen Owens; Lisa M Cordes; Amy Hankin; Anna Couvillon; Erin Nichols; Marijo Bilusic; Michael L Beshiri; Kathleen Kelly; Venkatesh Krishnasamy; Sunmin Lee; Min-Jung Lee; Akira Yuno; Jane B Trepel; Maria J Merino; Ryan Dittamore; Jennifer Marté; Renee N Donahue; Jeffrey Schlom; Keith J Killian; Paul S Meltzer; Seth M Steinberg; James L Gulley; Jung-Min Lee; William L Dahut Journal: J Immunother Cancer Date: 2018-12-04 Impact factor: 13.751
Authors: Daniel Castellano; Andrea B Apolo; Camillo Porta; Jaume Capdevila; Santiago Viteri; Cristina Rodriguez-Antona; Lidia Martin; Pablo Maroto Journal: Ther Adv Med Oncol Date: 2022-07-30 Impact factor: 5.485